Clayton Financial Group LLC Halozyme Therapeutics, Inc. Transaction History
Clayton Financial Group LLC
- $137 Billion
- Q3 2025
A detailed history of Clayton Financial Group LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Clayton Financial Group LLC holds 17 shares of HALO stock, worth $1,136. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17Holding current value
$1,136% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding HALO
# of Institutions
615Shares Held
127MCall Options Held
408KPut Options Held
388K-
Black Rock Inc. New York, NY17.6MShares$1.18 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.2MShares$819 Million0.01% of portfolio
-
State Street Corp Boston, MA5.94MShares$397 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA3.47MShares$232 Million0.03% of portfolio
-
Snyder Capital Management L P San Francisco, CA3.4MShares$227 Million3.92% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $9.32B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...